Last reviewed · How we verify

calcipotriene + clobetasol propionate

Leon Kircik, M.D. · FDA-approved active Small molecule

calcipotriene + clobetasol propionate is a Topical combination therapy (vitamin D analog + corticosteroid) Small molecule drug developed by Leon Kircik, M.D.. It is currently FDA-approved for Plaque psoriasis, Psoriatic dermatitis. Also known as: Sorilux foam + Olux E foam.

Calcipotriene is a vitamin D analog that regulates skin cell differentiation and proliferation, while clobetasol propionate is a potent corticosteroid that suppresses inflammation and immune response in the skin.

Calcipotriene is a vitamin D analog that regulates skin cell differentiation and proliferation, while clobetasol propionate is a potent corticosteroid that suppresses inflammation and immune response in the skin. Used for Plaque psoriasis, Psoriatic dermatitis.

At a glance

Generic namecalcipotriene + clobetasol propionate
Also known asSorilux foam + Olux E foam
SponsorLeon Kircik, M.D.
Drug classTopical combination therapy (vitamin D analog + corticosteroid)
TargetVitamin D receptor (VDR) and glucocorticoid receptor (GR)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Calcipotriene binds to vitamin D receptors on keratinocytes and immune cells, promoting normal differentiation and reducing hyperproliferation characteristic of psoriasis. Clobetasol propionate, a Class I (super-potent) topical corticosteroid, activates glucocorticoid receptors to rapidly reduce inflammation, itching, and erythema. The combination provides synergistic anti-inflammatory and anti-proliferative effects for enhanced efficacy in psoriatic plaques.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about calcipotriene + clobetasol propionate

What is calcipotriene + clobetasol propionate?

calcipotriene + clobetasol propionate is a Topical combination therapy (vitamin D analog + corticosteroid) drug developed by Leon Kircik, M.D., indicated for Plaque psoriasis, Psoriatic dermatitis.

How does calcipotriene + clobetasol propionate work?

Calcipotriene is a vitamin D analog that regulates skin cell differentiation and proliferation, while clobetasol propionate is a potent corticosteroid that suppresses inflammation and immune response in the skin.

What is calcipotriene + clobetasol propionate used for?

calcipotriene + clobetasol propionate is indicated for Plaque psoriasis, Psoriatic dermatitis.

Who makes calcipotriene + clobetasol propionate?

calcipotriene + clobetasol propionate is developed and marketed by Leon Kircik, M.D. (see full Leon Kircik, M.D. pipeline at /company/leon-kircik-m-d).

Is calcipotriene + clobetasol propionate also known as anything else?

calcipotriene + clobetasol propionate is also known as Sorilux foam + Olux E foam.

What drug class is calcipotriene + clobetasol propionate in?

calcipotriene + clobetasol propionate belongs to the Topical combination therapy (vitamin D analog + corticosteroid) class. See all Topical combination therapy (vitamin D analog + corticosteroid) drugs at /class/topical-combination-therapy-vitamin-d-analog-corticosteroid.

What development phase is calcipotriene + clobetasol propionate in?

calcipotriene + clobetasol propionate is FDA-approved (marketed).

What are the side effects of calcipotriene + clobetasol propionate?

Common side effects of calcipotriene + clobetasol propionate include Skin atrophy, Burning or stinging at application site, Folliculitis, Hypercalcemia (with systemic absorption).

What does calcipotriene + clobetasol propionate target?

calcipotriene + clobetasol propionate targets Vitamin D receptor (VDR) and glucocorticoid receptor (GR) and is a Topical combination therapy (vitamin D analog + corticosteroid).

Related